tbuckley/cabot-search huggingface dataset:
Reports of Marihuana for Glaucoma Treatment Are Misleading; Researchers Will Study
Journal: JAMA (1979)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Tunnel travelling
Authors: K Laitinen
Journal: BMJ (1994)

of the recommendations made by members of the Vascular Surgical Societyl 3 and of the findings in the Scottish report.'In general, this situation shows the need for well informed independent advice to purchasers.Clinical directors and vascular surgeons in trusts will inevitably provide advice that accords with the level of service available.Purchasers have to take advice either from experts outside the locality or from specialists in public health medicine who have knowledge of the relevant clinical and service issues and can assess the situation dispassionately.
Correction
Journal: BMJ (1921)

I MXDICAL JO_ D--children with high myopia now tstablished in connexion with the elementary school systelml, and( working after the model inaugurated in London.This scheme of educationi can be secured in some public schools by favour of the hea(l masters.Mr. Bishop Harman, wvho has oversighit of the Loindon blind schlools and myope classes, infQrms us that this boy would notbe admitted to a mvope class, but entered for a blinid school.His vision would be too bad to do the work of the myope class, and the grave risk of fuirther deterioration of vision makes it necessary that the boy should learn Braille at a time when lie can do it with the greatest ease; so that,
Protection against hepatitis A by an inactivated vaccine
Authors: B. L. Innis
Journal: JAMA (1994)

<h3>Objective.</h3> —To evaluate the safety and efficacy of a new inactivated hepatitis A vaccine. <h3>Design.</h3> —Double-blind randomized controlled trial stratified by community. <h3>Setting.</h3> —Community-based in Thailand. <h3>Study Participants.</h3> —A total of 40119 children, aged 1 to 16 years, attending 148 primary schools: 38 157 (95%) entered surveillance a mean of 138 days after receiving vaccine dose 1; 33 586 (84%) completed the controlled trial of 532 days; and 31 075 (81%) received crossover vaccine and remained under surveillance until day 844. <h3>Intervention.</h3> —Participants received hepatitis A vaccine or control hepatitis B vaccine starting January 7,1991 (doses in months 0,1, and 12), and crossed over to the alternate vaccine 18 months later. <h3>Main Outcome Measure.</h3> —Cases of hepatitis A (symptoms, alanine aminotransferase levels of 45 U/L or higher, and IgM to hepatitis A virus) were identified by evaluating school absences of 2 or more days. <h3>Results.</h3> —There were no serious adverse reactions despite administration of more than 109000 doses of hepatitis A vaccine. Among initially seronegative recipients of two doses of hepatitis A vaccine, the proportion with 20 mlU/mL or more of antibody to hepatitis A virus before and 5 months after a 1-year booster was 94% and 99%, respectively. Of 6976 episodes of illness during the controlled trial, there were 40 cases of hepatitis A; 38 were in the control group. Of the 40 cases, six, all in controls, occurred after the 1-year booster dose. Following two doses of hepatitis A vaccine (days 138 through 386), protective efficacy was 94% (95% confidence interval, 79% to 99%); cumulative efficacy including the postbooster period (days 138 to 532) was 95% (95% confidence interval, 82% to 99%). The two hepatitis A vaccine recipients who had symptomatic infections (257 and 267 days after dose 1) appeared to have been partially protected since their illnesses were brief and associated with only slight increases in alanine aminotransferase. <h3>Conclusions.</h3> —Inactivated hepatitis A vaccine is safe; when administered in two doses, it protects against hepatitis A for at least 1 year. (<i>JAMA</i>. 1994;271:1328-1334)
THE ABUSE OF THE BROMIDS.
Journal: JAMA (1896)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Blood Clots and Abnormal Vessels of the Inferior Vena Cava
Journal: Annals of Internal Medicine (2002)

Summaries for Patients1 January 2002Blood Clots and Abnormal Vessels of the Inferior Vena CavaSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-136-1-200201010-00005 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail What is the problem and what is known about it so far?Blood containing oxygen and vital nutrients is pumped to various parts of the body through blood vessels called arteries. After the body absorbs the oxygen and nutrients, blood returns to the heart and lungs through blood vessels called veins. Deep veins in the legs and pelvis join to form a large vein in the back of the abdomen (inferior vena cava), which carries blood from the lower part of the body to the heart. (The inferior vena cava is usually a single large vein that forms from many ... Author, Article, and Disclosure InformationAffiliations: The summary below is from the full report titled “Anomalies of the Inferior Vena Cava in Patients with Iliac Venous Thrombosis.” It is in the 1 January 2002 issue of Annals of Internal Medicine (volume 136, pages 37-41). The authors are A Obernosterer, M Aschauer, W Schnedl, and RW Lipp.Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine. Previousarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoAnomalies of the Inferior Vena Cava in Patients with Iliac Venous Thrombosis Andrea Obernosterer , Manuela Aschauer , Wolfgang Schnedl , and Rainer W. Lipp Metrics Cited byUse of hydrogen as a carrier gas for the analysis of steroids with anabolic activity by gas chromatography–mass spectrometry 1 January 2002Volume 136, Issue 1Page: I-69KeywordsBlood flowBlood vesselsHeartInferior vena cavaNutrientsOxygenPelvisThrombosisUltrasound imagingVeins ePublished: 1 January 2002 Issue Published: 1 January 2002 Copyright & PermissionsCopyright © 2002 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
The Pan-American Medical Congress.
Journal: JAMA (1892)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
NEURASTHENIA.
Authors: I. N. LOVE
Journal: JAMA (1994)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
FASEB Evaluation of Possible Carcinogenicity of Selected Drugs and Cosmetic Ingredients
Journal: JNCI Journal of the National Cancer Institute (1984)

Journal Article FASEB Evaluation of Possible Carcinogenicity of Selected Drugs and Cosmetic Ingredients Get access JNCI: Journal of the National Cancer Institute, Volume 72, Issue 3, March 1984, Pages 770–771, https://doi.org/10.1093/jnci/72.3.770-c Published: 01 March 1984
A. Raymond Dochez, MD, Dies at 82
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE ETIOLOGY OF TROPICAL SPLENOMEGALY.
Journal: JAMA (1904)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Neonatal herpes
Authors: G. A. Manuel
Journal: JAMA (1987)

<h3>To the Editor.—</h3> The problem of maternal asymptomatic herpes simplex virus (HSV) shedding that resulted in neonatal herpes was highlighted by Growdon et al.<sup>1</sup>We describe our experience of asymptomatic viral shedding in a high-risk, childbearing-age group who presented for exclusion of sexually transmitted diseases. <h3>Study.—</h3> A total of 3165 consecutive, new, or repeat-visit female patients were screened primarily to detect<i>Chlamydia trachomatis</i>infection, from Aug 13,1984, to April 18,1985. However, the same cervical specimens also were used to inoculate human embryo lung fibroblast cells for the isolation of HSV. The collection of specimens and the method of isolation have been described elsewhere.<sup>2</sup><i>Chlamydia trachomatis</i>and HSV were isolated from the cervical specimens of 533 (16.8%) and 72 (2.2%) women, respectively. In the group with HSV, 23 women (32%) had neither a history nor any genital lesions suggestive of HSV infection. Thus one third of the women with
Wilms´Tumor 1 Protein Is Highly Expressed on Malignant Plasma Cells and Provides a Novel Target for Immunotherapeutic Approaches
Authors: Guenther Koehne, Satyajit Kosuri, Ekaterina Doubrovina, Tao Dao, Andrew Scott, Achim A Jungbluth, Richard J O'Reilly
Journal: Blood (2015)
International medical education
Journal: JAMA (1969)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Highlights
Journal: JAMA Oncology (2017)

Genetic Mutations and Gastrointestinal Stromal Tumors 602In this exploratory analysis of a clinical trial, Joensuu and colleagues investigated the effect of KIT and PDGFRA mutations on recurrence-free survival (RFS) in patients with gastrointestinal stromal tumors treated with surgery and adjuvant imatinib.Patients were randomized to receive adjuvant imatinib for 1 or 3 years; those with a deletion in KIT exon 11 had better RFS when receiving 3 years of adjuvant imatinib, and those with other genotypes had little or no benefi t.The authors conclude that mutation analysis can help aid in patient selection for adjuvant imatinib treatment.
Commentaire de travail de T. Ishizuka et al., pp. 428
Journal: Endoscopy (2007)

See also: Submucosal injection, for endoscopic mucosal resection, of photocrosslinkable chitosan hydrogel in DMEM/F12 mediumEndoscopy 2007; 39(05): 428-433DOI: 10.1055/s-2007-966393
Iatrogenic Diseases
Authors: David M. Spain
Journal: JAMA (1972)

It is good to see a publication on iatrogenic diseases in paperback form. The subject is currently in such a state of conceptual flux that a book published on the subject one year becomes almost useless the following year. Furthermore, where encyclopedic factual information is needed on the contraindications to the use of drugs and their harmful effects, there are always available the annual<i>AMA Drug Evaluations and the Physician's Desk Reference</i>. The currently reviewed book on iatrogenic diseases, therefore, serves to supplement these references by zeroing in on special problem areas, and to present further insight into the dynamics and pathogenesis of some of these adverse reactions. The introductory chapter on the epidemiologic aspects of iatrogenic diseases provides sobering figures as to the extent and growth of this problem, one which will remain with us in the foreseeable future. A drug interaction chapter calls attention to one of the
Valsalva: Riv Bimest Oto-Rino-Laring, Rome
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 4851: Kinase domain activation of FGFR2 yields high-grade lung adenocarcinoma sensitive to a pan-FGFR inhibitor in a mouse model of NSCLC
Authors: Esra A. Akbay, Jeremy H. Tchaicha, Abigail Altabef, Oliver R. Mikse, Eiki Kikuchi, Kevin Rhee, Rachel Liao, Roderick T. Bronson, Lynette M. Sholl, Matthew Meyerson, Peter S. Hammerman, Kwok-Kin Wong
Journal: Cancer Research (2014)

Abstract Somatic mutations in Fibroblast Growth Factor Receptor 2 (FGFR2) have been found in 4-5% of patients diagnosed with non-small cell lung cancer (NSCLC). FGFR2 and other FGFR kinase family gene alterations have been found in lung squamous cell carcinoma, adenocarcinoma, and other malignancies though mouse models of FGFR driven lung cancers have not been reported. Here, we generated a genetically engineered mouse model (GEMM) of NSCLC driven by a kinase domain mutation in FGFR2. Combined with p53 ablation, primary grade III/IV adenocarcinoma was induced in the lung epithelial compartment exhibiting locally invasive and pleiotropic tendencies largely made up of multinucleated cells. Tumors were acutely sensitive to pharmacological inhibition of FGFR signaling. In preliminary studies tumors also responded to Programmed death pathway immune checkpoint blockade using anti-PD-1 antibody arguing for activated immune evasion mechanisms in this model.This is the first autochthonous FGFR2-driven lung cancer GEMM that can be applied across different cancer indications in a preclinical setting. Citation Format: Esra A. Akbay, Jeremy H. Tchaicha, Abigail Altabef, Oliver R. Mikse, Eiki Kikuchi, Kevin Rhee, Rachel Liao, Roderick T. Bronson, Lynette M. Sholl, Matthew Meyerson, Peter S. Hammerman, Kwok-Kin Wong. Kinase domain activation of FGFR2 yields high-grade lung adenocarcinoma sensitive to a pan-FGFR inhibitor in a mouse model of NSCLC. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 4851. doi:10.1158/1538-7445.AM2014-4851
Essentials of Genito-Urinary and Venereal Diseases Arranged in the Form of Questions and Answers, Prepared Especially for Students of Medicine.
Journal: JAMA (1906)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal